Related Experiment Video

Updated: Jun 19, 2026

Development and Application of Rapamycin-regulated Tyrosine Phosphatases
06:56

Development and Application of Rapamycin-regulated Tyrosine Phosphatases

Published on: September 6, 2024

Rapamycin (sirolimus) in tuberous sclerosis associated pediatric central nervous system tumors

Catherine Lam1, Eric Bouffet, Uri Tabori

  • 1Division of Haematology/Oncology, Neuro-oncology Program, The Hospital for Sick Children, Toronto, Canada.

Pediatric Blood & Cancer
|October 27, 2009
PubMed

Insights

Tuberous sclerosis complex (TSC) patients with subependymal giant cell astrocytomas (SEGAs) may benefit from rapamycin therapy. This review highlights rapamycin

Area of Science:

  • Neuro-oncology
  • Genetics
  • Pharmacology

Background:

  • Tuberous sclerosis complex (TSC) is a genetic disorder characterized by hamartomatous growths.
  • Subependymal giant cell astrocytomas (SEGAs) are common brain tumors in TSC patients.
  • Traditional therapies like chemotherapy and radiation show limited efficacy for SEGAs.

Observation:

  • Recent studies indicate rapamycin's effectiveness in treating TSC-associated tumors.
  • This suggests a potential shift in management strategies for SEGAs.

Findings:

  • Rapamycin demonstrates potential benefits for TSC patients with SEGAs.
  • The review summarizes institutional experience and literature on rapamycin therapy.
  • Potential benefits and hazards of rapamycin for syndromal brain tumors are discussed.

Implications:

  • Rapamycin therapy may become a standard treatment for TSC-associated SEGAs.
  • Oncologists' involvement in SEGA management is likely to increase.
  • Further research into rapamycin's efficacy and safety in TSC is warranted.

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...